From: Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
OR (95% CI)a | |
---|---|
Fatigue | 0.34 (0.18–0.65) |
Sleeping problems | 0.22 (0.07–0.67) |
Irritable | 0.29 (0.12–0.71) |
Fever | 1.01 (0.22–4.71) |
Cough | 0.51 (0.22–1.17) |
Common cold | 0.50 (0.27–0.91) |
Listless/apathetic | 0.24 (0.10–0.55) |
Dyspnea | 0.81 (0.25–2.65) |
Headache | 0.70 (0.38–1.29) |
Decreased appetite | 0.55 (0.21–1.45) |
Vomiting | 0.20 (0.02–1.77) |
Diarrhea | 0.57 (0.19–1.73) |
Lower abdominal pain | 0.57 (0.26–1.25) |
Nausea | 0.66 (0.27–1.66) |
Dizziness | 0.73 (0.31–1.71) |
Fainting | Did not converge |
Myalgia | 1.04 (0.60–1.78) |
Joint pain | 0.44 (0.15–1.27) |
Muscular spasm | 1.75 (0.61–5.01) |
Sweating | Did not converge |
Rash | 0.39 (0.16–0.99) |
Itch | 0.43 (0.17–1.07) |
Other | 0.81 (0.25–2.61) |
All systemic events | 0.43 (0.23–0.81) |